FMR LLC Sells Shares of Beam Therapeutics

FMR LLC sold 251,488 shares of Beam Therapeutics Inc. (NasdaqGS:BEAM) on June 26, 2026. The shares were sold at an average price of $35.26, totaling approximately $8.87 million.

Insider Buying and Selling at Beam Therapeutics Inc.

FMR LLC's recent sale on June 26 wasn't the only activity in Beam Therapeutics' insider transactions. On June 25, they sold another 33,372 shares at an average price of $35.12. Meanwhile, Giuseppe Ciaramella, the President, bought 35,505 shares on June 17 at a price of $0.96.

Other Institutional Activity in Beam Therapeutics

Several institutions have adjusted their positions in Beam Therapeutics. FMR LLC itself increased its holdings by 543,061 shares, ending with 12,452,199 shares valued at about $296.7 million. ARK Investment Management LLC reduced its stake by 333,756 shares, now holding 12,133,433 shares worth around $289.1 million. Farallon Capital Management LLC added 71,585 shares, bringing its total to 10,134,696 shares valued at $241.5 million. BlackRock, Inc. and State Street Corp also added to their positions, with State Street Corp increasing its holdings by 470,736 shares to a total of 5,699,265 shares valued at approximately $135.8 million.

Beam Therapeutics Inc. Stock Up 19.2%

Shares of Beam Therapeutics Inc. traded near $34.81 on Monday. The company has a market cap of about $3.58 billion and a forward P/E ratio of -7.34, indicating it is not currently profitable. The stock's 52-week range is between $15.60 and $36.88, with a 50-day moving average of $30.69 and a 200-day moving average of $27.36. Beam's current ratio is 16.99, suggesting strong liquidity.

Recent Earnings

Beam Therapeutics reported revenue of $164.01 million, reflecting a growth rate of 3.25%. However, the company posted a net margin of -40.23% and a return on equity of -5.77%, indicating ongoing financial challenges. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On May 13, 2026, Bernstein maintained its buy rating on Beam Therapeutics with a price target of $39. Citigroup also kept its buy rating, setting a target of $68 on March 26. The consensus among analysts is a strong buy, with a mean target price of $51.07 based on 15 analyst opinions.

About Beam Therapeutics

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing precision genetic medicines targeting serious diseases. The company is engaged in several programs, including treatments for sickle cell disease and other genetic conditions. Beam collaborates with prominent firms like Pfizer and Verve Therapeutics to advance its research and development initiatives. Led by CEO John M. Evans, Beam employs around 522 people.

Bottom Line

FMR LLC's recent sale of Beam Therapeutics shares is part of ongoing institutional activity in the company. Beam Therapeutics continues to draw interest due to its innovative genetic medicine programs. Investors should note that insider transactions like these are reported after the fact and may not reflect current positions.